Stefan Kochanek
Overview
Explore the profile of Stefan Kochanek including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
102
Citations
2006
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wienen F, Nilson R, Allmendinger E, Peters S, Barth T, Kochanek S, et al.
Mol Ther Oncol
. 2025 Jan;
32(4):200909.
PMID: 39758252
Human adenovirus type 5 (HAdV-5)-based oncolytic viruses hold significant promise for anti-cancer therapy. However, poor tumor-targeting and off-target organ transduction after systemic administration limit their therapeutic efficacy. In addition, the...
2.
Zhao S, Tschulakow A, Karthikeyan S, Wang K, Kochanek S, Schraermeyer U, et al.
FASEB Bioadv
. 2024 Oct;
6(9):311-326.
PMID: 39399476
Retinopathy of prematurity (ROP) is a severe retinal disease in premature infants characterized by pathological neovascularization, obliteration of retinal vessels and increased vessel tortuosity. Currently, there are no completely satisfactory...
3.
Wagner M, Zhu G, Khalid F, Phan T, Maity P, Lupu L, et al.
Neurobiol Dis
. 2024 Sep;
201:106668.
PMID: 39284372
Cockayne syndrome (CS) is an autosomal recessive disorder of developmental delay, multiple organ system degeneration and signs of premature ageing. We show here, using the RNA-seq data from two CS...
4.
Seefelder M, Kochanek S, Klein F
Sci Rep
. 2024 Jun;
14(1):13277.
PMID: 38858475
Colocalization, the spatial overlap of molecular entities, is often key to support their involvement in common functions. Existing colocalization tools, however, face limitations, particularly because of their basic statistical analysis...
5.
Purde M, Cupovic J, Palmowski Y, Makky A, Schmidt S, Rochwarger A, et al.
Mol Ther
. 2023 Dec;
32(2):426-439.
PMID: 38058126
Harnessing the immune system to eradicate tumors requires identification and targeting of tumor antigens, including tumor-specific neoantigens and tumor-associated self-antigens. Tumor-associated antigens are subject to existing immune tolerance, which must...
6.
Pflumm D, Seidel A, Klein F, Gross R, Krutzke L, Kochanek S, et al.
Front Immunol
. 2023 Sep;
14:1231274.
PMID: 37753087
A multitude of alterations in the old immune system impair its functional integrity. Closely related, older individuals show, for example, a reduced responsiveness to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)...
7.
Reale A, Krutzke L, Cadamuro M, Vitiello A, von Einem J, Kochanek S, et al.
Int J Mol Sci
. 2023 Jun;
24(11).
PMID: 37298206
Oncolytic viruses (OVs) are promising therapeutics for tumors with a poor prognosis. An OV based on herpes simplex virus type 1 (oHSV-1), talimogene laherparepvec (T-VEC), has been recently approved by...
8.
Nilson R, Krutzke L, Wienen F, Rojewski M, Zeplin P, Funk W, et al.
Viruses
. 2023 Jan;
15(1).
PMID: 36680258
Human multipotent mesenchymal stromal cells (hMSCs) are of significant therapeutic interest due to their ability to deliver oncolytic adenoviruses to tumors. This approach is also investigated for targeting head and...
9.
Wienen F, Nilson R, Allmendinger E, Graumann D, Fiedler E, Bosse-Doenecke E, et al.
Biomater Adv
. 2022 Nov;
144:213208.
PMID: 36442453
Introduction: Treatment of head and neck squamous cell carcinomas (HNSCC) by oncolytic adenoviral vectors holds promise as an efficient anti-cancer therapy. The epidermal growth factor receptor (EGFR) represents an attractive...
10.
Buoninfante A, Andeweg A, Baker A, Borad M, Crawford N, Dogne J, et al.
NPJ Vaccines
. 2022 Nov;
7(1):141.
PMID: 36351906
No abstract available.